| Pharmaceutical Information |
| Drug Name |
Sargramostim |
| Drug ID |
BADD_D01990 |
| Description |
Sargramostim is a human recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) expressed in yeast. It is a glycoprotein that is 127 residues. Substitution of Leu23 leads to a difference from native protein. |
| Indications and Usage |
For the treatment of cancer and bone marrow transplant |
| Marketing Status |
approved; investigational |
| ATC Code |
L03AA09 |
| DrugBank ID |
DB00020
|
| KEGG ID |
D05803
|
| MeSH ID |
C081222
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
D0XT5Y
|
| NDC Product Code |
71837-5843 |
| UNII |
5TAA004E22
|
| Synonyms |
sargramostim | 23-L-leucine-colony-stimulating factor 2 (human clone pHG25 protein moiety) | Leukine | Prokine |
|
| Chemical Information |
| Molecular Formula |
Not Available |
| CAS Registry Number |
123774-72-1 |
| SMILES |
Not Available |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
